Publication Name	World Journal of Clinical Cases
Manuscript ID	3460
Country	Italy

Received	2013-05-01 13:46
Peer-Review Started	2013-05-03 13:37
First Decision by Editorial Office Director
Return for Revision	2013-06-07 10:34
Revised
Publication Fee Transferred
Second Decision by Editor	2013-07-17 18:18
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2013-07-18 13:32
Articles in Press
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-07-31 15:28
Publish the Manuscript Online	2013-08-07 10:29

ISSN	2307-8960 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Long lasting response to second-line everolimus in kidney cancer
Manuscript Source	Invited Manuscript
All Author List	Antonella Virtuoso, Tania Policastro, Michela Izzo, Piera Federico, Carlo Buonerba, Pasquale Rescigno and Giuseppe Di Lorenzo
Funding Agency and Grant Number
Corresponding Author	Giuseppe Di Lorenzo, MD, PhD, Deparment of Clinical Medicine, University Federico Ⅱ of Naples, Via Pansini, 5, 80131 Naples, Italy. giuseppedilorenzoncol@hotmail.com
Key Words	Metastatic renal cell carcinoma; Everolimus (RAD001); Sunitinib; Progression-free survival
Core Tip	Everolimus (RAD001) is an orally administered inhibitor of the mammalian target of rapamycin pathway. Everolimus is recommended for the second line therapy of metastatic renal cell carcinoma after a Tyrosine kinase inhibitor. In the case presented here, everolimus was administered after first line therapy with sunitinib. The prolonged progression-free survival (PFS) obtained with everolimus in this case is of peculiar interest, as it is a multiple of the median PFS obtained in with everolimus in the regulatory trial.
Publish Date	2013-08-07 10:29
Citation	Virtuoso A, Policastro T, Izzo M, Federico P, Buonerba C, Rescigno P, Di Lorenzo G. Long lasting response to second-line everolimus in kidney cancer. World J Clin Cases 2013; 1(5): 166-168
URL	http://www.wjgnet.com/2307-8960/full/v1/i5/166.htm
DOI	http://dx.doi.org/10.12998/wjcc.v1.i5.166

Full Article (PDF)	WJCC-1-166.pdf
Manuscript File	3460-Review.doc
Answering Reviewers	3460-Answering reviewers.pdf
Copyright License Agreement	3460-Copyright assignment.doc
Non-Native Speakers of English Editing Certificate	3460-Language certificate.doc
Peer-review Report	3460-Peer review(s).pdf
Scientific Editor Work List	3460-Scientific editor work list.doc